{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T16:17:22Z","timestamp":1788452242813,"version":"build-2803163510"},"reference-count":10,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,3]]},"DOI":"10.1182\/blood.2026034919","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:31:50Z","timestamp":1788449510000},"page":"1223-1224","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["A CAR against rejection: dual-targeting allogeneic T cells"],"prefix":"10.1182","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7951-1580","authenticated-orcid":false,"given":"Philip","family":"Bucher","sequence":"first","affiliation":[{"name":"1University of T\u00fcbingen"},{"name":"2University Hospital T\u00fcbingen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Leibold","sequence":"additional","affiliation":[{"name":"1University of T\u00fcbingen"},{"name":"2University Hospital T\u00fcbingen"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"10","key":"2026090311314691900_bib1","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1182\/blood.2025032112","article-title":"A novel triple-knockout allogeneic BCMA CAR T-cell therapy (CT0590) in multiple myeloma: preclinical and phase 1 study","volume":"148","author":"Jin","year":"2026","journal-title":"Blood"},{"issue":"1","key":"2026090311314691900_bib2","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s40164-025-00654-3","article-title":"Addressing graft-versus-host disease in allogeneic cell-based immunotherapy for cancer","volume":"14","author":"Lyu","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"2026090311314691900_bib3","doi-asserted-by":"crossref","first-page":"118986","DOI":"10.1016\/j.biopha.2026.118986","article-title":"Current status and perspective of off-the-shelf CAR-T cells in cancer immunotherapy","volume":"195","author":"Fallahianshafiei","year":"2026","journal-title":"Biomed Pharmacother"},{"issue":"7","key":"2026090311314691900_bib4","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/j.cell.2018.10.028","article-title":"NKG2A blockade potentiates CD8 T cell immunity induced by cancer vaccines","volume":"175","author":"van Montfoort","year":"2018","journal-title":"Cell"},{"issue":"10","key":"2026090311314691900_bib5","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1016\/j.ymthe.2024.06.022","article-title":"Immunosuppressant therapy averts rejection of allogeneic FKBP1A-disrupted CAR-T cells","volume":"32","author":"Maldini","year":"2024","journal-title":"Mol Ther"},{"issue":"11","key":"2026090311314691900_bib6","doi-asserted-by":"crossref","first-page":"e833","DOI":"10.1016\/S2352-3026(22)00245-9","article-title":"UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial","volume":"9","author":"Benjamin","year":"2022","journal-title":"Lancet Haematol"},{"key":"2026090311314691900_bib7","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2026.02.008","article-title":"Stealth designs to overcome allorejection in engineered cell therapy","author":"Li","year":"11  2026","journal-title":"Trends Immunol"},{"issue":"8059","key":"2026090311314691900_bib8","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/s41586-025-08657-0","article-title":"HIV immune evasin Nef enhances allogeneic CAR T cell potency","volume":"640","author":"Perica","year":"2025","journal-title":"Nature"},{"issue":"1","key":"2026090311314691900_bib9","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/s41392-024-02005-w","article-title":"Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization","volume":"9","author":"Chen","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"20","key":"2026090311314691900_bib10","doi-asserted-by":"crossref","first-page":"e2427216122","DOI":"10.1073\/pnas.2427216122","article-title":"Quadruple adenine base\u2013edited allogeneic CAR T cells outperform CRISPR\/Cas9 nuclease\u2013engineered T cells","volume":"122","author":"Engel","year":"2025","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/10\/1223\/2541915\/blood_bld-2026-034919-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/10\/1223\/2541915\/blood_bld-2026-034919-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:31:52Z","timestamp":1788449512000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/148\/10\/1223\/570563\/A-CAR-against-rejection-dual-targeting-allogeneic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9,3]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2026034919","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,3]]},"published":{"date-parts":[[2026,9,3]]}}}